Clinical Trials Sponsored by ArmaGen, Inc

Total 36989 results

Amgen

Terminated

AMG 761 in Adults With Asthma

Asthma

United States
Amgen

Completed

A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab

Osteoporosis | Postmenopausal Osteoporosis | Low Bone Mineral Density | Low Bone Mass
Amgen

Terminated

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Pancreatic Cancer | Esophageal Cancer | Lung Cancer
Amgen

Completed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Cancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
Amgen

Completed

Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Asthma
Amgen

Completed

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

Secondary Hyperparathyroidism
Amgen

Completed

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Anemia | Non-Myeloid Malignancies
Amgen

Terminated

Darbepoetin Alfa and Anemia of Cancer

Neoplasms | Carcinoma | Cancer | Anemia | Non-Myeloid Malignancies | Anemia of Cancer
Amgen

Completed

Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

Colorectal Cancer | Metastatic Cancer
Amgen

Terminated

Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint (APPRISE 1)

Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Cancer | Lung Neoplasms | Non-Small Cell Lung Cancer | Thrombocytopenia | Lung Cancer | Solid Tumors | Oncology | Chemotherapy-Induced Thrombocytopenia

United States, Canada, Italy, Germany, Austria, Hungary, Portugal, Ireland
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States, Australia, New Zealand
Amgen

Completed

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Anemia
Amgen

Completed

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma
Amgen

Completed

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Secondary Hyperparathyroidism | Chronic Renal Insufficiency
Amgen

Completed

A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

Hyperparathyroidism, Primary
Amgen

Completed

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Cancer | Anemia | Non-Myeloid Malignancies
Amgen

Completed

NESP Pediatric Study

End Stage Renal Disease | Pre-dialysis
Amgen

Completed

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Chronic Kidney Disease | Kidney Disease
Amgen

Completed

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Cancer | Anemia
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy

Anemia | Solid Tumors
Amgen

Completed

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

Gastrointestinal Cancer
Amgen

Completed

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Anemia
Amgen

Completed

Treatment for Subjects With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis
Amgen

Completed

A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)

Anemia | Secondary Hyperparathyroidism
Amgen

Completed

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Canada
Amgen

Completed

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer
Amgen

Terminated

An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial

Heart Failure | Cardiovascular Disease | Anemia | Ventricular Dysfunction | Congestive Heart Failure
Amgen

Completed

A Research Study for Patients With End-Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

Osteoporosis | Osteopenia
Amgen

Completed

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Postmenopausal Osteoporosis
Amgen

Completed

FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

Neutropenia
Amgen

Completed

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Tumors
Amgen

Completed

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Osteopenia
Amgen

Completed

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Cancer | Anemia | Non-Myeloid Malignancies
Amgen

Completed

Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis

Nephrology
Amgen

Completed

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Breast Cancer
Amgen

Completed

STAAR-3 Clinical Study

Chronic Kidney Disease | Chronic Renal Insufficiency | Kidney Disease | Pre-dialysis | Pre-ESRD
Amgen

Completed

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes
Amgen

Completed

Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)

Rheumatoid Arthritis
Amgen

Completed

A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects

Anemia | Congestive Heart Failure
Amgen

Completed

STAAR-1 Clinical Study

Chronic Kidney Disease | Chronic Renal Insufficiency | Kidney Disease | Pre-dialysis | Pre-ESRD
Amgen

Completed

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Metastatic Colorectal Cancer
Amgen

Completed

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Solid Tumors | Oncology | Tumors
Amgen

Completed

An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis

Psoriasis
Amgen

Completed

Fixed Dose NESP Study in Subjects With CRI

Pre-Dialysis
Amgen

Completed

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

Chronic Kidney Disease | Kidney Disease

3

Subscribe